May 8 |
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
|
May 8 |
Tarsus Pharmaceuticals GAAP EPS of -$1.01 beats by $0.18, revenue of $27.61M beats by $9.71M
|
May 8 |
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
|
May 7 |
Tarsus Pharmaceuticals Q1 2024 Earnings Preview
|
May 6 |
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
|
May 1 |
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
|
Apr 23 |
Tarsus refinances existing debt with $200M financing commitment
|
Apr 23 |
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
|
Apr 19 |
Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%
|
Apr 8 |
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
|